| Clinical and Regulatory | |
|---|---|
| Event Type: | Phase 1/2 Results |
| Timing: | Q4 2016 |
| Designation(s): | None |
|
This event is set for a broad date range and therefore the exact timing is unknown. This adds a degree of risk.
|
|
| Disease and Treatment | |
|---|---|
| Disease: | Oncology |
| Indication: | Acute Lymphoblastic Leukemia in Adults |
| Lead Indication?: | Yes |
| Treatment Name: | KTE-C19 |
|
Likelihood of event success varies depending on disease, treatment and lead indication classification.
|
|
| Company Information | |
|---|---|
| Co. Name: | Kite Pharma |
| Stock Symbol: | KITE |
| Shares Traded: | NASDAQ |
|
The OTC BB and OTC Markets have less stringent reporting and financial requirements than the NASDAQ and NYSE. This may increase the level of risk for investors. Smaller size may have an influence on likelihood of success.
|
|
| Event Status | |
|---|---|
| Event Outcome: | Ongoing |
| Event Discussion: | Forums |
| Event Announcement(s): | http://ir.kitepharma.com/releasedetail.cfm?ReleaseID=994338 |
| Partnership: | No |
|
Partnerships help smaller biotech companies finance the long approval process. Partnership also provides validation the clinical program may be a worthy investment.
|
|
Detailed Event Description from Company Announcement
Quote
Kite is advancing its KTE-C19 pipeline with ongoing and expanded ZUMA studies to evaluate six additional indications:
- ZUMA-2: Mantle cell lymphoma (MCL), with initial Phase 2 data expected in 2017
- ZUMA-3: Adult acute lymphoblastic leukemia (Adult ALL), with initial Phase 1 data expected in 2016
- ZUMA-4: Pediatric acute lymphoblastic leukemia (Pediatric ALL), with initial Phase 1 data expected in 2016
- ZUMA-5: Indolent NHL, with first patient enrolled expected in the first quarter of 2017
- ZUMA-7: 2nd line DLBCL, with first patient enrolled expected in 2017
- ZUMA-8: Chronic lymphocytic leukemia (CLL), with first patient enrolled expected in 2017